Baicheng Pharmaceutical (Zhuhai Hengqin) Co., Ltd.

The main purpose of the study is to compare the pharmacokinetics of HQ2304 capsules (specifications: 10mg/1100mg, 20mg/1100mg) and the control drug Rabeprazole Sodium Enteric-coated Tablets (trade name: Polite®, specifications: 10mg, 20mg) in healthy Chinese subjects after a single dose in the fasting state; to provide a reference for the design of subsequent trials. The secondary purpose of the study is to evaluate the safety and tolerability of HQ2304 capsules and the control drug Rabeprazole Sodium Enteric-coated Tablets in healthy Chinese subjects.

To investigate the safety, tolerability and pharmacokinetic characteristics of a single injection of HQ2216 injection in healthy adult subjects in China, and to compare its bioavailability and pharmacokinetic/pharmacodynamic characteristics with those of control drugs, so as to provide a theoretical basis for dose selection in subsequent studies.